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INTRODUCTION 
Insulin-like growth factor (IGF-1) is a small peptide, molecular weight 7647 and shares structural similarities with 
the insulin molecule [1]. It is also known as Somatomedin C [2]. Initially, it was termed as sulfation factor [3]. It 
was also known to show non-suppressible insulin-like activity (NSILA) [4].  
 
In 1970’s these names were replaced by somatomedins [5]. By 1980’s, it was labelled as insulin-like growth 
factor possibly because of its similarities to the  insulin molecule [2,5]. Primarily, IGF-1 is produced by the liver. 
But since, it is also released from the target tissues, it is responsible for its paracrine and autocrine function [6].  
In intrauterine life, IGF-1 is present at approximately 20% of its normal range [7]. IGF-1 levels fluctuates with 
age; the lowest levels are found in infancy and old age, while peak are seen at puberty [8]. 
 
Regulation of IGF-1 
There are different factors that regulate IGF-1 level in serum such as age, nutrition, growth hormone, and some 
other hormones. However, growth hormone and nutrition are considered as the prime regulators of IGF-1 
expression on liver. The IGF-1 level in serum varies with age, where very low concentration in infancy that reach 
to the maximum level at puberty and then gradually tapering off till old age. This phenomenon is called 
"Somatopause" [8]. 
Nutrition also plays an important role in regulation of IGF-1. Deprivation of energy and protein leads to significant 
decline in the serum levels, while on the other hand, some minerals and dairy products boost up the IGF-1 level 
[9].  
Growth hormone (GH) is the main regulator of IGF-1. GH stimulates the liver and other target tissues to 
synthesize IGF-1 which then gets released in free form and binds to high-affinity carrier proteins (IGFBP) in 
serum. More than 99 percent of IGF-1 exists in the serum bound to IGFBP. High level of IGF-1 in serum has 
negative feedback on the pituitary gland which inhibits the secretion of GH [10]. 
Children with congenital hypothyroidism have generally low level of IGF-1. It is observed that the IGF-1 levels 
increases while treating them with thyroxine. In contrast estrogen has an insignificant role in the regulation of 
IGF-1 [11]. 
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ABSTRACT 
Human growth and development occur as a result of numerous processes which gets initiated under the 
influence of endocrine hormones. Insulin-like growth factor 1 (IGF-1) plays a most pivotal role in the growth 
and organ development of a child. IGF-1 is a peptide that belongs to somatomedins group of hormones, 
also known as somatomedin C. It releases from the liver and other tissues under the influence of growth 
hormone (GH). The liver is the main protagonist source of IGF-1 hence any disease that can cause liver 
dysfunction will eventually lead to growth impairment. During the period of growth regulation with GH 
therapy in liver disease and/or post liver transplantation, the persistent deficiency of IGF-1 proves to be a 
big challenge to therapy. Growth hormone therapy together with IGF-1 infusion can lead to good results on 
growth. Therefore, it is important to focus on IGF- level in serum along with Growth hormone while treating 
a child with poor growth in chronic liver disease and after liver transplantation. The role of IGF-1 therapy 
should also be considered for better growth and development. 
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Mechanism of Action 
 
IGF act as a   primary mediator of growth under the 
influence of growth hormone [12]. Growth hormone 
also influences its secretion from liver and other 
target tissue like bone, cartilage, and some solid 
organs; except before birth, where its secretion is not 
influenced by growth hormone [13]. 
 
The secretion of GH from somatotroph cells in the 
anterior pituitary gland exerts it effects via two 
routes. By acting upon growth hormone receptors 
(GHR, it stimulates the liver and other target tissues 
to release IGF-1 which leads to an increase in linear 
growth of the children [13].  
 
In serum, as already mentioned above, IGF-1 is found 
in two forms, free and bounded to IGFBP form. Later 
on, it binds to IGF-1 receptors on cells and triggers 
intracellular cascade series of signals that lead to cell 
growth, differentiation, and   transformation [14]. It 
has been also depicted in figure 1. 
 
Figure 1.  Secretion of IGF-1 from different routes. 
 
The numbers in the figure 1 are as follows 
 
1. Appetite centre,  
2. Signal transduction in liver cells,  
3. Release of IGF-1 from binding proteins, 
4. IGF-1 expression in growth plate,  
5. Proliferation of chondrocytes at growth plate. 
 
 
Role of IGF-1 in Growth Regulation 
 
IGF-1 has growth promoting effects, with dependent 
or independent of growth hormone. Growth hormone 
accelerates its action to help in regultaion of somatic 
growth and organ development in children. It has been 
seen in animal studies that it also plays an important 
role in brain development [15-18]. 
 
IGF-1 has the significant role in the linear growth and 
skeletal development [10]. IGF-1 releases from both of 
the mechanisms, from the liver and the target tissues 
are important for normal postnatal growth. The major 
fetal factor is thought to be IGF-2 while postnatal 
growth is mostly by IGF-1 and genetic studies show 
that they contribute equally to final height [19,20]. 
 
The pygmies of Africa were reported to be born with 
congenital anomalies which made them unable to 
synthesize a significant amount of IGF-1 and 
subsequently, resulted in small stature, regardless of 
the growth hormone levels [21]. 
 
IGF-1 not only helps in somatic growth but also has an 
influence on the pulsatile releases of GnRH at a 
different stage of age that determine the onset of 
puberty [22]. Few studies also show that IGF-1 also 
plays an important role in developing the cognitive 
function of the brain  while decrease in GH has a 
boosting effect on cognition [23-24]. 
 
IGF-1 in Liver Dysfunction 
 
The liver is the source of most (75%) of plasma IGF-1 
which is crucial for growth and development of 
children [6]. Hence, any factor that causes impairment 
of IGF-1 levels can notably influence the growth 
processes. 
 
Chronic liver disease is a major factor that leads to 
decrease in linear growth, probably due to the low 
level of IGF-1 in serum and IGFBP, where IGFBP has 
comparatively less role because it is also secreted from 
other tissues [25,26].   
 
In liver dysfunction, IGF-1 level gets decreased by two 
possible mechanisms, a decrease in GH receptors and 
decrease synthesis from liver. 
 
In beta Thalassemia major, child present with a growth 
and maturation delay, particularly in which body is 
disproportionately shortened truncal wise but 
extremities shall be normal generally. This abnormal or 
poor growth is due to variety of factors including 
decrease levels of IGF-1 which plays the fundamental 
role in growth regulation [27]. 
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Similarly, in another chronic liver disease such as 
chronic Cholestatic liver disease, a decrease in bone 
mass devalues the GH therapy. However, studies 
showed that alteration in IGF-1 level in chronic 
Cholestatic disease has a great impact on it [27].  
 
In patients of chronic liver disease waiting for liver 
transplant, generally show resistance to GH, so here 
IGF-1 therapy should be considered [28]. 
 
Effects of IGF-1 therapy 
 
Children with chronic liver disease present with 
impaired growth and short stature secondary to 
decrease food intake, malabsorption and 
abnormalities of GH-IGF system, including resistance 
to GH [29]. 
 
The chronic liver disease leads to low level of IGF-1 in 
serum while growth hormone stays normal. Such is a 
case of cystic fibrosis in which the patient presents 
with poor growth because of the low level of IGF- 1, 
hence treating them with rGH can improve growth 
impairment to some extent probably due to 
increasing production of IGF-1 from the liver [28,30]. 
 
Nutritional deficiency also occurs in CLD that 
contributes to growth impairment, therefore IGF-1 
infusion into a human whose on sub-optimal nutrition 
restores nitrogen balance to normal. Similarly, co-
administration of GH and IGF-1 induces positive 
nitrogen balance in calorically restricted humans [31]. 
 
IGF-1 therapy is effective in children with GH 
insensitivity due to GH receptor mutation. FDA has 
approved 2 drugs that contain recombinant IGF-1, 
alone and together with GH which if given to the 
patient can boosts up growth in a child with IGF-1 
deficiency [32]. 
 
A child with CLD/end-stage liver disease (ESLD) 
doesn't respond well to growth hormone 
replacement therapy possibly because of persistent 
deficiency of IGf-1. Therefore, co-administration of 
GH and IGF-1 in these patients help in good catching 
up on growth. 
 
The best way to prevent this disorder, is to educate 
the parents and children including the adolescents, so 
that if there is disorder, then proper treatment can be 
given.  
 
Now a days, even the children and adolescents are 
well educated and have great health awareness, 
which has helped in decreasing many disorders [33]. 
Hence, the role of IGF-1 therapy should also be 
considered for better growth and development. 
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